Surface immunoglobulin (Ig)-positive B cell acute lymphoblastic leukemia (B-ALL) comprises 2-3% of pediatric ALL. All other B-lineage ALL are precursor-B-ALL without surface Ig expression but positive for the nuclear enzyme terminal deoxynucleotidyl transferase (TdT), which is regarded to be an immature lymphoid marker.
1
There are two main subtypes of BL: the sporadic and the endemic subtype. Sporadic BL occurs worldwide, whereas endemic BL is predominantly found in African countries. The sites of disease may vary between the two groups, eg orbital masses and jaw tumors are seen almost exclusively in the endemic subtype. 2 In both B-ALL and BL, translocations involving the c-MYC gene are found. Translocation (8;14)(q24;q32) involving the Ig heavy chain gene (IGH) is identified in ෂ85% of cases, whereas the remainder of cases generally have one of the two variant translocations t(2;8)(p11;q24) and t(8;22)(q24q11) involving the Ig kappa (IGK) and Ig lambda (IGL) light chain genes, respectively. As a result of these translocations the c-MYC gene is overexpressed. It has been shown that c-MYC translocations are essential, but not sufficient to induce B-ALL or BL. 2 According to the latest WHO classification of hematopoietic malignancies, B-ALL with FAB-L3 morphology are regarded to be equivalent to BL in leukemic phase and should be diagnosed likewise.
3,4 B-ALL and BL are considered to be similar in biology, oncogenic event, and treatment response, but comparison of their immunogenotype has not been possible, because the specific characteristics of the Ig heavy chain (IGH) gene rearrangements, somatic hypermutation status, and intraclonal heterogeneity have not been reported for B-ALL so far. We therefore addressed the question whether immunogenotype of B-ALL is similar to that of BL or to that of precursor-B-ALL. For this purpose we analyzed the immunogenotype of 12 B-ALL and five BL (four sporadic and one endemic).
Southern blot analysis was performed to determine the configuration of the IGH locus and the presence of clonal EBV genome (Table  1) . In only one B-ALL was clonal EBV present. Most sporadic BL are also negative for EBV, whereas EBV is almost invariably present in endemic BL. 2 The IGH locus was further studied by PCR-heteroduplex analysis for the presence of complete (V H -D H -J H ) and incomplete (D H -J H ) rearrangements, followed by sequencing of the clonal rearrangements (Table 1) . Remarkably, in nine out of 12 cases (75%) incomplete D H -J H rearrangements were detected on the second allele, which was much higher than in our BL control group where in only one of the five patients an incomplete rearrangement was found. No further literature data are available about incomplete D H -J H rearrangements in BL. The frequency of incomplete rearrangements in precursor-B-ALL is 22% (Szczepań ski et al, submitted) .
In all B-ALL patients somatic mutations were found in the V H gene segments. This is in strong contrast to precursor-B-ALL, which do not have somatically mutated V genes (van der Burg et al, unpublished results Leukemia an average of 2.7 ± 1.8% (Table 1) . In patient 12 a stop codon was formed as the result of a somatic mutation, explaining the unusual absence of surface Ig expression in this patient. The presence of somatic mutations suggests that B-ALL originate from a (post)-germinal center B cell. The frequency of somatic mutations in B-ALL is lower as compared to BL: sporadic BL (n = 27) with 4.6 ± 3.1%, endemic BL (n = 12) with 7.9 ± 3.9%, and AIDS-associated BL (n = 8) with 7.5 ± 3.6% (Table 2 ). However, due to the wide range in frequencies of somatic mutations, the difference between B-ALL and sporadic BL was not statistically significant (P Ͼ 0.05, using 2 test). There was no evidence for antigen selection in the B-ALL series, because the ratio between replacement and silent mutations (R/S ratio) was comparable for the frame work (FR) sequences and the complementary determining regions (CDR) ( Table 1 ). In antigen-selected B cells the R/S ratio of the mutations in the CDR sequences is generally higher than the R/S ratio of the mutations in the FR sequences.
The presence of ongoing mutations resulting in intraclonal heterogeneity was studied by sequencing six to nine individual clones of the cloned PCR products of the in-frame rearrangements. The frequency of intraclonal variation was not higher than the Taq enzyme error rate of 0.11% (data not shown), ie 0.3 mutations per V H clone. Therefore no clear indication for intraclonal heterogeneity in these cases was observed (Table 1) . Intraclonal heterogeneity has been observed in two out of 47 BL cases (see Table 2 ). 5 The presence of somatic mutations indicates that B-ALL do not arise from immature B cells, as the name might suggest, but from a postgerminal center B cell. The moderate frequency of somatic mutations and low frequency of EBV positivity are comparable to sporadic BL ( Table 2 ). The obtained Ig gene data indicate that B-ALL differ significantly from the other types of B-lineage ALL, which all represent precursor-B-ALL. In combination with the known similarities in biology, oncogenic event and treatment response between B-ALL and BL, the immunogenotypic data presented here support the view to replace the term B-ALL and diagnose all B-ALL patients as stage IV BL.
3 This is fully in line with the newly recognized WHO disease category Burkitt's leukemia-lymphoma. 4 Analogous to the term T-ALL for T-lineage ALL, the term B-ALL could then be reserved for B-lineage ALL, ie ALL of B cell precursor origin. f Mean number of intraclonal mutation differences per clone with the number of sequenced clones between brackets.
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g As a result of somatic mutation a stop codon was formed in the V H region (AAA (Lys) into TAA (stop)) explaining the absence of surface Ig expression in this patient. The growth of highly proliferative acute lymphoblastic leukemia may be independent of stroma and/or angiogenesis TO THE EDITOR Lymphoproliferative diseases, like acute leukemia (AL) in children, have potential to invade locally and infiltrate a variety of different tissues other than bone marrow, ie central nervous system or testis. The mechanisms of tumoral invasion involved in solid tumors are related to angiogenesis, endothelial adhesion and cell migration. Recent studies have hypothesized similar mechanisms for hemopathies, especially AL. 1 It has been suggested that angiogenesis could participate in AL cell proliferation, and therefore the secretion of modulators of angiogenesis such as bFGF has been considered as a possible indicator of the leukemic proliferation. The importance of angiogenic factors is not fully established. These angiogenic cytokines seem to be produced by leukemic and/or bone marrow (BM) microenvironmental cells. 2 Recently, Veiga et al 2 have shown a contact-dependent interaction between acute lymphoblastic leukaemia (ALL) cells of patients and BM endothelium in presence of angiogenic cytokines. This interaction leads to the survival of leukemic cells by maintaining the expression of anti-apoptotic genes. A recent study showed that high levels of cellular VEGF are significantly correlated with shorter survival in adult acute myeloblastic leukemia (AML) patients with high WBC at diagnosis (P Ͻ 0.04), whereas no association was found with the plasma levels of bFGF.
3 However, no correlation between angiogenesis and the prognosis of ALL has been described yet.
In a series of children with ALL, we found a correlation between usual poor prognostic features and the interactions between leukemic cells and BM microenvironment. Twenty-three newly diagnosed pro-B and pre-B-lineage ALL were studied for the urinary secretion of angiogenic cytokines (bFGF, VEGF). Diagnosis was established on BM aspirates and classification was made according to the usual immunophenotyping and cytogenetics. All children were treated according to the French protocol FRALLE 93. 4 The urinary bFGF and VEGF levels
